Roadzen Inc (RDZN) Stock Analysis
Verdict: AVOID
Imminent dilution risk from a 4-month cash runway ($6.58M cash) undermines Roadzen's AI revenue growth and narrowing operating losses.
Investment score: 33/100
Analysis as of
Is Roadzen Inc stock worth reviewing? AI model thesis
The model views Roadzen (RDZN) as an unappealing microcap investment due to an urgent cash crunch ($6.58M cash vs -$21.28M annual FCF burn) that threatens severe stock dilution despite top-line growth.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 65/100 (weight 10%)
- Analyst Consensus: 60/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Roadzen Inc opportunities and risks
What speaks for RDZN
- Sustained Revenue Growth & Narrowing Losses
What speaks against RDZN
- Imminent Equity Dilution & Short Cash Runway
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| RDZN | n/a | 1.7x | n/a | 60.7% | -46.9% | -23.6% |
| EGAN | 17.0x | 1.6x | 6.2x | 73.4% | 9.7% | 13.7% |
| DMRC | n/a | 3.6x | n/a | 57.1% | -99.8% | -4.2% |
| VERI | n/a | 1.1x | n/a | 52.6% | -118.3% | -53.8% |
| AEYE | n/a | 2.2x | n/a | 78.4% | -10.9% | 6.3% |
| ROC | n/a | 4.9x | n/a | 79.8% | -38.7% | -10.0% |
| Peer median | n/a | 2.2x | n/a | 73.4% | -38.7% | -4.2% |
Frequently asked questions about Roadzen Inc (RDZN)
Is RDZN stock a good investment?
The cached TradeMates AI model rates Roadzen Inc as AVOID with an investment score of 33/100. The model views Roadzen (RDZN) as an unappealing microcap investment due to an urgent cash crunch ($6.58M cash vs -$21.28M annual FCF burn) that threatens severe stock dilution despite top-line growth. This is algorithmic model output, not personal investment advice.
Is RDZN stock a buy?
The TradeMates model verdict for RDZN is AVOID with an investment score of 33/100. Treat this as a model signal to review, not a personal buy recommendation.